Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
RxNorm 05-Oct-2026 · geprüft 2026-10-26 · 1181 Präparate · 62955 Quellenpassagen · 167 strukturierte Aussagen. Automatisch aktualisiert, ohne menschliche Freigabe.
Wechselwirkungen · Norvir
Norvir 100 mg powder for oral suspension · Abschnitt 4.5 · PDF-Seite 13–14
HOS-086211 · Präparat HOS-083284
13
Ritonavir effects on Non-antiretroviral Co-administered Medicinal Products
Co-administered Medicinal Products Dose of Co- Dose of Effect on Co- Effect on Co-
administered NORVIR (mg) administered administered
Medicinal Products Medicinal Medicinal Products
(mg) Products Cmax
AUC
Apalutamide Apalutamide is a moderate to strong CYP3A4 inducer and this may lead to a
decreased exposure of ritonavir and potential loss of virologic response. In addition,
serum concentrations may be increased when co-administered with ritonavir
resulting in the potential for serious adverse events including seizure.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): apalutamide (HOS-086212) lead (HOS-085592)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-11T18:35:00Z · SHA-256 82413695e61cf39577e85c47e382ee60197570a4ae72fe81d6e24e4211cd2d43 · Passage ba5746604de1afb25f74f3c3b6daa06ef29a317243a44cdc2149a2f49dedebf0 · Zeichen 16562–17664 im Abschnitt
Wechselwirkungen · Norvir
Norvir 100 mg powder for oral suspension · Abschnitt 4.5 · PDF-Seite 14
HOS-086213 · Präparat HOS-083284
Concomitant use of ritonavir with apalutamide is not recommended.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): apalutamide (HOS-086212)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-11T18:35:00Z · SHA-256 82413695e61cf39577e85c47e382ee60197570a4ae72fe81d6e24e4211cd2d43 · Passage 7e9058c5ed3f950e2a30fc05499c73676335033c9de83cda0bafb04fca167a80 · Zeichen 17703–17768 im Abschnitt
Wechselwirkungen · Norvir
Norvir 100 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 46
HOS-086419 · Präparat HOS-083284
Apalutamide Apalutamide is a moderate to strong CYP3A4 inducer and this may lead to a decreased
exposure of ritonavir and potential loss of virologic response. In addition, serum
concentrations may be increased when co-administered with ritonavir resulting in the
potential for serious adverse events including seizure.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): apalutamide (HOS-086212) lead (HOS-085592)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-11T18:35:00Z · SHA-256 82413695e61cf39577e85c47e382ee60197570a4ae72fe81d6e24e4211cd2d43 · Passage 144cc3ead9e7eb41d451c15c0a441b7c96f925f6982a0cfb1d6432b76ab724d3 · Zeichen 18001–18460 im Abschnitt
Wechselwirkungen · Norvir
Norvir 100 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 46
HOS-086420 · Präparat HOS-083284
Concomitant use of ritonavir with apalutamide is not recommended.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): apalutamide (HOS-086212)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-11T18:35:00Z · SHA-256 82413695e61cf39577e85c47e382ee60197570a4ae72fe81d6e24e4211cd2d43 · Passage 7e9058c5ed3f950e2a30fc05499c73676335033c9de83cda0bafb04fca167a80 · Zeichen 18500–18565 im Abschnitt
Wechselwirkungen · Kaletra
Kaletra (80 mg + 20 mg) / ml oral solution · Abschnitt 4.5 · PDF-Seite 12–13
HOS-108863 · Präparat HOS-093083
12
CYP3A4 inhibition by concomitantly administered with
lopinavir/ritonavir. Kaletra.
Antianginal
Ranolazine Due to CYP3A inhibition by The concomitant administration of
lopinavir/ritonavir, concentrations Kaletra and ranolazine is
of ranolazine are expected to contraindicated (see section 4.3).
increase.
Antiarrhythmics
Amiodarone, Dronedarone Amiodarone, Dronedarone: Concomitant administration of
Concentrations may be increased Kaletra and amiodarone or
due to CYP3A4 inhibition by dronedarone is contraindicated (see
lopinavir/ritonavir. section 4.3) as the risk of
arrhythmias or other serious
adverse reactions may be
increased.
Digoxin Digoxin: Caution is warranted and
Plasma concentrations may be therapeutic drug monitoring of
increased due to P-glycoprotein digoxin concentrations, if
inhibition by lopinavir/ritonavir. available, is recommended in case
The increased digoxin level may of co-administration of Kaletra and
lessen over time as P-gp digoxin. Particular caution should
induction develops. be used when prescribing Kaletra
in patients taking digoxin as the
acute inhibitory effect of ritonavir
on P-gp is expected to significantly
increase digoxin levels. Initiation
of digoxin in patients already
taking Kaletra is likely to result in
lower than expected increases of
digoxin concentrations.
Bepridil, Systemic Bepridil, Systemic Lidocaine, Caution is warranted and
Lidocaine, and Quinidine Quinidine: therapeutic drug concentration
Concentrations may be increased monitoring is recommended when
when co-administered with available.
lopinavir/ritonavir.
Antibiotics
Clarithromycin Clarithromycin: For patients with renal impairment
Moderate increases in (CrCL < 30 ml/min) dose reduction
clarithromycin AUC are expected of clarithromycin should be
due to CYP3A inhibition by considered (see section 4.4).
lopinavir/ritonavir. Caution should be exercised in
administering clarithromycin with
Kaletra to patients with impaired
hepatic or renal function.
Anticancer agents and kinase inhibitors
Abemaciclib Serum concentrations may be Co-administration of abemaciclib
increased due to CYP3A and Kaletra should be avoided. If
inhibition by ritonavir. this co-administration is judged
unavoidable, refer to the
abemaciclib SmPC for dosage
adjustment recommendations.
Monitor for ADRs related to
abemaciclib.
Apalutamide Apalutamide is a moderate to Decreased exposure of Kaletra may
strong CYP3A4 inducer and this result in potential loss of
may lead to a decreased exposure virological response.
of lopinavir/ritonavir.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): dronedarone (HOS-086144) abemaciclib (HOS-086209) lidocaine (HOS-108866) apalutamide (HOS-086212) bepridil (HOS-085612) quinidine (HOS-085593) digoxin (HOS-086172) lead (HOS-085592) clarithromycin (HOS-084517) amiodarone (HOS-085596) ranolazine (HOS-086141)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-02T16:00:00Z · SHA-256 441d9e5f9e4b42d645e4bd802abc892cef6574b0be5b3f18d2a96678774ae365 · Passage 2a6dc58dcb1aed961671098b7774afc6ab5284838d7c3becb73533d81f884e22 · Zeichen 9077–14069 im Abschnitt
Wechselwirkungen · Kaletra
Kaletra (80 mg + 20 mg) / ml oral solution · Abschnitt 4.5 · PDF-Seite 13–14
HOS-108871 · Präparat HOS-093083
13
In addition, co-administration of
Serum concentrations of apalutamide and Kaletra may lead
apalutamide may be increased to serious adverse events including
due to CYP3A inhibition by seizure due to higher apalutamide
lopinavir/ritonavir. levels. Concomitant use of Kaletra
with apalutamide is not
recommended.
Afatinib Afatinib: Caution should be exercised in
AUC: ↑ administering afatinib with Kaletra.
(Ritonavir 200 mg twice Cmax: ↑ Refer to the afatinib SmPC for
daily) dosage adjustment
The extent of increase depends on recommendations. Monitor for
the timing of ritonavir ADRs related to afatinib.
administration.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): apalutamide (HOS-086212) lead (HOS-085592) afatinib (HOS-086207)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-02T16:00:00Z · SHA-256 441d9e5f9e4b42d645e4bd802abc892cef6574b0be5b3f18d2a96678774ae365 · Passage f48ebca72aeed138d4efab9192a46cc17fc35f03ff4c66b8dc408c547f269793 · Zeichen 14113–15428 im Abschnitt
Wechselwirkungen · Kaletra
Kaletra 200 mg/50 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 49–50
HOS-109006 · Präparat HOS-093083
49
Antiarrhythmics
Amiodarone, Amiodarone, Dronedarone: Concomitant administration of
Dronedarone Concentrations may be increased Kaletra and amiodarone or
due to CYP3A4 inhibition by dronedarone is contraindicated (see
lopinavir/ritonavir. section 4.3) as the risk of arrhythmias
or other serious adverse reactions
may be increased.
Digoxin Digoxin: Caution is warranted and therapeutic
Plasma concentrations may be drug monitoring of digoxin
increased due to P-glycoprotein concentrations, if available, is
inhibition by lopinavir/ritonavir. recommended in case of
The increased digoxin level may co-administration of Kaletra and
lessen over time as P-gp digoxin. Particular caution should be
induction develops. used when prescribing Kaletra in
patients taking digoxin as the acute
inhibitory effect of ritonavir on P-gp
is expected to significantly increase
digoxin levels. Initiation of digoxin
in patients already taking Kaletra is
likely to result in lower than expected
increases of digoxin concentrations.
Bepridil, Systemic Bepridil, Systemic Lidocaine, Caution is warranted and therapeutic
Lidocaine, and Quinidine: drug concentration monitoring is
Quinidine Concentrations may be increased recommended when available.
when co-administered with
lopinavir/ritonavir.
Antibiotics
Clarithromycin Clarithromycin: For patients with renal impairment
Moderate increases in (CrCL < 30 ml/min) dose reduction
clarithromycin AUC are expected of clarithromycin should be
due to CYP3A inhibition by considered (see section 4.4). Caution
lopinavir/ritonavir. should be exercised in administering
clarithromycin with Kaletra to
patients with impaired hepatic or
renal function.
Anticancer agents and kinase inhibitors
Abemaciclib Serum concentrations may be Co-administration of abemaciclib
increased due to CYP3A and Kaletra should be avoided. If
inhibition by ritonavir. this co-administration is judged
unavoidable, refer to the abemaciclib
SmPC for dosage adjustment
recommendations. Monitor for
ADRs related to abemaciclib.
Apalutamide Apalutamide is a moderate to Decreased exposure of Kaletra may
strong CYP3A4 inducer and this result in potential loss of virological
may lead to a decreased exposure response.
of lopinavir/ritonavir. In addition, co-administration of
apalutamide and Kaletra may lead to
Serum concentrations of serious adverse events including
apalutamide may be increased due seizure due to higher apalutamide
to CYP3A inhibition by levels. Concomitant use of Kaletra
lopinavir/ritonavir. with apalutamide is not
recommended.
Afatinib Afatinib: Caution should be exercised in
AUC: ↑ administering afatinib with Kaletra.
(Ritonavir 200 mg twice Cmax: ↑ Refer to the afatinib SmPC for
daily)
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): dronedarone (HOS-086144) abemaciclib (HOS-086209) lidocaine (HOS-108866) apalutamide (HOS-086212) bepridil (HOS-085612) quinidine (HOS-085593) digoxin (HOS-086172) lead (HOS-085592) afatinib (HOS-086207) clarithromycin (HOS-084517) amiodarone (HOS-085596)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-02T16:00:00Z · SHA-256 441d9e5f9e4b42d645e4bd802abc892cef6574b0be5b3f18d2a96678774ae365 · Passage e2bfc1f119ab72d4142e3587fc0d81da448b5ce69a5003d6154afba7723f33c1 · Zeichen 9850–14882 im Abschnitt
Wechselwirkungen · Kaletra
Kaletra 100 mg/25 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 85–86
HOS-109081 · Präparat HOS-093083
85
Apalutamide Apalutamide is a moderate to Decreased exposure of Kaletra may
strong CYP3A4 inducer and this result in potential loss of virological
may lead to a decreased exposure response.
of lopinavir/ritonavir. In addition, co-administration of
apalutamide and Kaletra may lead
Serum concentrations of to serious adverse events including
apalutamide may be increased seizure due to higher apalutamide
due to CYP3A inhibition by levels. Concomitant use of Kaletra
lopinavir/ritonavir. with apalutamide is not
recommended.
Afatinib Afatinib: Caution should be exercised in
AUC: ↑ administering afatinib with Kaletra.
(Ritonavir 200 mg twice Cmax: ↑ Refer to the afatinib SmPC for
daily) dosage adjustment
The extent of increase depends on recommendations. Monitor for
the timing of ritonavir ADRs related to afatinib.
administration.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): apalutamide (HOS-086212) lead (HOS-085592) afatinib (HOS-086207)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-02T16:00:00Z · SHA-256 441d9e5f9e4b42d645e4bd802abc892cef6574b0be5b3f18d2a96678774ae365 · Passage 971ba5f06e732c816a73e515413ab0dc3ebf3e2bfd8aed1958a5e05c3ad90825 · Zeichen 13946–15481 im Abschnitt
Gegenanzeigen · Reyataz
REYATAZ 200 mg hard capsules REYATAZ 300 mg hard capsules · Abschnitt 4.3 · PDF-Seite 4
HOS-112045 · Präparat HOS-093615
Co-administration with medicinal products that are strong inducers of CYP3A4 due to the potential for
loss of therapeutic effect and development of possible resistance (e.g., rifampicin, St. John's wort,
apalutamide, encorafenib, ivosidenib, carbamazepine, phenobarbital and phenytoin) (see section 4.5).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): phenobarbital (HOS-085617) carbamazepine (HOS-085618) apalutamide (HOS-086212) encorafenib (HOS-086222) ivosidenib (HOS-112046) phenytoin (HOS-084531)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-29T13:00:00Z · SHA-256 ff5481974bd7c752b73fa0c147cf3e96fc892edc735359fa71817833db471beb · Passage 359af65d22480ed37cfcfaef1bbfcb565d3d5ae0d963e074b6096b3714364fe4 · Zeichen 1124–1428 im Abschnitt
Gegenanzeigen · Reyataz
REYATAZ 50 mg oral powder · Abschnitt 4.3 · PDF-Seite 40
HOS-112153 · Präparat HOS-093615
Co-administration with medicinal products that are strong inducers of CYP3A4 due to the potential for
loss of therapeutic effect and development of possible resistance (e.g., rifampicin, St. John's wort,
apalutamide, encorafenib, ivosidenib, carbamazepine, phenobarbital and phenytoin) (see section 4.5).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): phenobarbital (HOS-085617) carbamazepine (HOS-085618) apalutamide (HOS-086212) encorafenib (HOS-086222) ivosidenib (HOS-112046) phenytoin (HOS-084531)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-29T13:00:00Z · SHA-256 ff5481974bd7c752b73fa0c147cf3e96fc892edc735359fa71817833db471beb · Passage 359af65d22480ed37cfcfaef1bbfcb565d3d5ae0d963e074b6096b3714364fe4 · Zeichen 982–1286 im Abschnitt
Wechselwirkungen · Reyataz
REYATAZ 200 mg hard capsules REYATAZ 300 mg hard capsules · Abschnitt 4.5 · PDF-Seite 18–19
HOS-112101 · Präparat HOS-093615
18
Medicinal products by Interaction Recommendations concerning co-
therapeutic area administration
ANTINEOPLASTICS AND IMMUNOSUPRESSANTS
Antineoplastics
Apalutamide The mechanism of interaction is CYP3A4 Co-administration with REYATAZ
induction by apalutamide and CYP3A4 (with or without ritonavir) is
inhibition by atazanavir/ritonavir. contraindicated due to the potential
for decreased atazanavir and
ritonavir plasma concentration with
subsequent loss of virologic
response and possible resistance to
the class of protease inhibitors (see
section 4.3). In addition, serum
concentrations of apalutamide may
be increased when coadministered
with atazanavir/ritonavir, resulting
in the potential for serious adverse
events including seizure.
Encorafenib The mechanism of interaction is CYP3A4 Co-administration of encorafenib
inhibition by atazanavir and/or ritonavir. with REYATAZ (with or without
ritonavir) is contraindicated due to
the potential for loss of virologic
response, development of
resistance, increase in encorafenib
plasma concentration and
subsequent risk of serious adverse
events such as QT interval
prolongation (see section 4.3).
Ivosidenib The mechanism of interaction is CYP3A4 Co-administration of ivosidenib
inhibition by atazanavir and/or ritonavir. with REYATAZ (with or without
ritonavir) is contraindicated due to
potential for loss of virologic
response, development of
resistance, increase in ivosidenib
plasma concentration and
subsequent risk of serious adverse
events such as QT interval
prolongation (see section 4.3).
Irinotecan Atazanavir inhibits UGT and may interfere If REYATAZ is co-administered
with the metabolism of irinotecan, with irinotecan, patients should be
resulting in increased irinotecan toxicities. closely monitored for adverse
events related to irinotecan.
Immunosuppressants
Cyclosporin Concentrations of these More frequent therapeutic
Tacrolimus immunosuppressants may be increased concentration monitoring of these
Sirolimus when co-administered with REYATAZ medicinal products is recommended
due to CYP3A4 inhibition. until plasma levels have been
stabilised.
CARDIOVASCULAR AGENTS
Antiarrhythmics
Amiodarone, Concentrations of these antiarrhythmics Caution is warranted and
Systemic lidocaine, may be increased when co-administered therapeutic concentration
Quinidine with REYATAZ. The mechanism of monitoring is recommended when
amiodarone or systemic available. The concomitant use of
lidocaine/atazanavir interaction is CYP3A quinidine is contraindicated
inhibition. Quinidine has a narrow (see section 4.3).
therapeutic window and is contraindicated
due to potential inhibition of CYP3A by
REYATAZ.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): protease (HOS-085623) lidocaine (HOS-108866) apalutamide (HOS-086212) quinidine (HOS-085593) encorafenib (HOS-086222) tacrolimus (HOS-085202) ivosidenib (HOS-112046) sirolimus (HOS-085172) ritonavir (HOS-084521) amiodarone (HOS-085596) irinotecan (HOS-112102)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-29T13:00:00Z · SHA-256 ff5481974bd7c752b73fa0c147cf3e96fc892edc735359fa71817833db471beb · Passage c9ed9e0270f64ec8df603d7aa8f424ad74b96d960cc137508e6d9081efdb4558 · Zeichen 45345–51108 im Abschnitt
Wechselwirkungen · Reyataz
REYATAZ 50 mg oral powder · Abschnitt 4.5 · PDF-Seite 54
HOS-112191 · Präparat HOS-093615
Close monitoring of patient's
virologic response should be
exercised.
Lamotrigine Co-administration of lamotrigine and Lamotrigine should be used
REYATAZ/ritonavir may decrease with caution in combination
lamotrigine plasma concentrations due to with REYATAZ/ritonavir.
UGT1A4 induction.
If necessary, monitor
lamotrigine concentrations and
adjust the dose accordingly.
ANTINEOPLASTICS AND IMMUNOSUPRESSANTS
Antineoplastics
Apalutamide The mechanism of interaction is CYP3A4 Co-administration with
induction by apalutamide and CYP3A4 REYATAZ (with or without
inhibition by atazanavir/ritonavir. ritonavir) is contraindicated
due to the potential for
decreased atazanavir and
ritonavir plasma concentration
with subsequent loss of
virologic response and possible
resistance to the class of
protease inhibitors (see
section 4.3). In addition, serum
concentrations of apalutamide
may be increased when
coadministered with
atazanavir/ritonavir, resulting
in the potential for serious
adverse events including
seizure.
Encorafenib The mechanism of interaction is CYP3A4 Co-administration of
inhibition by atazanavir and/or ritonavir. encorafenib with REYATAZ
(with or without ritonavir) is
contraindicated due to potential
for loss of virologic response,
development of resistance,
increase in encorafenib plasma
concentration and subsequent
risk of serious adverse events
such as QT interval
prolongation (see section 4.3).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lamotrigine (HOS-086242) protease (HOS-085623) apalutamide (HOS-086212) encorafenib (HOS-086222) ritonavir (HOS-084521)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-29T13:00:00Z · SHA-256 ff5481974bd7c752b73fa0c147cf3e96fc892edc735359fa71817833db471beb · Passage 76cd05b5753aea8ee1aca9c616b6de829a0e30efc35a847539ed861c81939295 · Zeichen 45824–49596 im Abschnitt
Wechselwirkungen · Advagraf
Advagraf 0.5 mg prolonged-release hard capsules Advagraf 1 mg prolonged-release hard capsules Advagraf 3 mg prolonged-release hard capsules Advagraf 5 mg prolonged-release hard capsules · Abschnitt 4.5 · PDF-Seite 11–12
HOS-116820 · Präparat HOS-094481
11
Drug/Substance Class or Drug interaction effect Recommendations concerning
Name co-administration
In vitro the following May increase tacrolimus whole Monitor tacrolimus whole
substances have been shown blood trough concentrations and blood trough concentrations
to be potential inhibitors of increase the risk of serious adverse and reduce tacrolimus dose if
tacrolimus metabolism: reactions (e.g., neurotoxicity, QT needed [see section 4.2].
bromocriptine, cortisone, prolongation) [see section 4.4]. Monitor renal function, ECG
dapsone, ergotamine, for QT prolongation, and other
gestodene, lidocaine, side effects closely.
mephenytoin, midazolam,
nilvadipine, norethisterone,
quinidine, tamoxifen
Strong CYP3A4 inducers: May decrease tacrolimus whole It is recommended that
rifampicin, phenytoin, blood trough concentrations and concomitant use should be
carbamazepine, apalutamide, increase the risk of rejection [see avoided. If unavoidable,
enzalutamide, mitotane, or section 4.4]. patients may require an
St. John’s wort (Hypericum Maximal effect on tacrolimus blood increase in tacrolimus dose.
perforatum) concentrations may be achieved 1-2 Changes in tacrolimus dose
weeks after co-administration. The should be individualized and
effect may remain 1-2 weeks after adjusted as needed based on
completion of the treatment. tacrolimus trough
concentrations, which should
be assessed at initiation,
monitored frequently
throughout (starting within the
first few days) and re-
evaluated on and after
completion of the CYP3A4
inducer. After use of the
CYP3A4 inducer has ended,
tacrolimus dose may need to
be adjusted gradually. Monitor
graft function closely.
Moderate CYP3A4 inducers: May decrease tacrolimus whole Monitor tacrolimus whole
metamizole, phenobarbital, blood trough concentrations and blood trough concentrations
isoniazid, rifabutin, increase the risk of rejection [see and increase tacrolimus dose if
efavirenz, etravirine, section 4.4]. needed [see section 4.2].
nevirapine; weak CYP3A4 Monitor graft function closely.
inducers: flucloxacillin
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): cortisone (HOS-114161) phenobarbital (HOS-085617) lidocaine (HOS-108866) carbamazepine (HOS-085618) rifabutin (HOS-086262) apalutamide (HOS-086212) tamoxifen (HOS-088380) quinidine (HOS-085593) etravirine (HOS-088088) mephenytoin (HOS-109801) mitotane (HOS-112479) bromocriptine (HOS-090620) efavirenz (HOS-087947) nilvadipine (HOS-116826) gestodene (HOS-116824) nevirapine (HOS-088064) ergotamine (HOS-086154) isoniazid (HOS-088590) dapsone (HOS-088141) phenytoin (HOS-084531) enzalutamide (HOS-116829) midazolam (HOS-086167)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-02-27T10:10:00Z · SHA-256 0ed42bc08ffe6bd7e6c8ed94445bdb8b8c9971dabe41ef3a899ec75fc2f97c0e · Passage 9f68b7412442537a87ae5cc4a11a2083ae7ee1d4f84bacfd72b3336085546560 · Zeichen 8467–12012 im Abschnitt
Wechselwirkungen · Modigraf
Modigraf 0.2 mg granules for oral suspension Modigraf 1 mg granules for oral suspension · Abschnitt 4.5 · PDF-Seite 11–12
HOS-209751 · Präparat HOS-154375
11
Drug/Substance Class or Drug interaction effect Recommendations concerning co-
Name administration
The effect on tacrolimus
blood concentrations may
remain for several days after
co-administration is
completed.
Moderate or weak CYP3A4 May increase tacrolimus Monitor tacrolimus whole blood
inhibitors: whole blood trough trough concentrations frequently,
antifungal agents (e.g., concentrations and increase starting within the first few days
fluconazole, isavuconazole, the risk of serious adverse of co-administration. Reduce
clotrimazole, miconazole), reactions (e.g., neurotoxicity, tacrolimus dose if needed [see
the macrolide antibiotics QT prolongation) [see section 4.2]. Monitor renal
(e.g., azithromycin), calcium section 4.4]. A rapid increase function, ECG for QT
channel blockers (e.g., in tacrolimus level may prolongation, and other side
nifedipine, nicardipine, occur. effects closely.
diltiazem, verapamil),
amiodarone, danazol,
ethinylestradiol, lansoprazole,
omeprazole, the HCV
antivirals elbasvir/grazoprevir
and glecaprevir/pibrentasvir,
the CMV antiviral letermovir,
and the tyrosine kinase
inhibitors nilotinib, crizotinib
and imatinib and (Chinese)
herbal remedies containing
extracts of Schisandra
sphenanthera
In vitro the following May increase tacrolimus Monitor tacrolimus whole blood
substances have been shown whole blood trough trough concentrations and reduce
to be potential inhibitors of concentrations and increase tacrolimus dose if needed [see
tacrolimus metabolism: the risk of serious adverse section 4.2].
bromocriptine, cortisone, reactions (e.g., neurotoxicity, Monitor renal function, ECG for
dapsone, ergotamine, QT prolongation) [see QT prolongation, and other side
gestodene, lidocaine, section 4.4]. effects closely.
mephenytoin, midazolam,
nilvadipine, norethisterone,
quinidine, tamoxifen
Strong CYP3A4 inducers: May decrease tacrolimus It is recommended that
rifampicin, phenytoin whole blood trough concomitant use should be
carbamazepine, apalutamide, concentrations and increase avoided. If unavoidable, patients
enzalutamide, mitotane or St. the risk of rejection [see may require an increase in
John’s wort (Hypericum section 4.4]. tacrolimus dose. Changes in
perforatum) Maximal effect on tacrolimus tacrolimus dose should be
blood concentrations may be individualized and adjusted as
achieved 1-2 weeks after co- needed based on tacrolimus
administration. The effect trough concentrations, which
may remain 1-2 weeks after should be assessed at initiation,
completion of the treatment. monitored frequently throughout
(starting within the first few days)
and re-evaluated on and after
completion of the CYP3A4
inducer. After use of the CYP3A4
inducer has ended, tacrolimus
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lansoprazole (HOS-085166) letermovir (HOS-090621) diltiazem (HOS-086288) elbasvir (HOS-108814) isavuconazole (HOS-085186) nifedipine (HOS-086289) cortisone (HOS-114161) nicardipine (HOS-090619) pibrentasvir (HOS-086298) lidocaine (HOS-108866) carbamazepine (HOS-085618) crizotinib (HOS-116818) apalutamide (HOS-086212) tamoxifen (HOS-088380) quinidine (HOS-085593) glecaprevir (HOS-086297) azithromycin (HOS-088112) clotrimazole (HOS-090574) mephenytoin (HOS-109801) calcium (HOS-085615) imatinib (HOS-110212) grazoprevir (HOS-108815) danazol (HOS-085473) mitotane (HOS-112479) fluconazole (HOS-087945) bromocriptine (HOS-090620) nilvadipine (HOS-116826) gestodene (HOS-116824) ergotamine (HOS-086154) amiodarone (HOS-085596) tyrosine (HOS-108875) dapsone (HOS-088141) phenytoin (HOS-084531) enzalutamide (HOS-116829) nilotinib (HOS-086218) miconazole (HOS-115630) midazolam (HOS-086167) omeprazole (HOS-085912) verapamil (HOS-090602)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-03-03T17:00:00Z · SHA-256 1a464ac051c5783e49ce08a9d103d0d319997aa4add60584450928c1b11144a7 · Passage 1e7cc303a6d0d182851c23281c6a79a17f96d714a9cddc0ab3d6ada78ab947ab · Zeichen 6985–10993 im Abschnitt
Wechselwirkungen · Envarsus
Envarsus 0.75 mg prolonged-release tablets Envarsus 1 mg prolonged-release tablets Envarsus 4 mg prolonged-release tablets · Abschnitt 4.5 · PDF-Seite 10–11
HOS-219155 · Präparat HOS-216331
10
Drug/Substance Class or Drug interaction effect Recommendations
Name concerning co-administration
concentrations. Monitor renal
function, ECG for QT
prolongation, and other side
effects closely.
Moderate or weak CYP3A4 May increase tacrolimus whole Monitor tacrolimus whole
inhibitors: blood trough concentrations and blood trough concentrations
antifungal agents (e.g., increase the risk of serious adverse frequently, starting within the
fluconazole, isavuconazole, reactions (e.g., neurotoxicity, QT first few days of co-
clotrimazole, miconazole), the prolongation) [see section 4.4]. A administration. Reduce
macrolide antibiotics (e.g., rapid increase in tacrolimus level tacrolimus dose if needed [see
azithromycin), calcium may occur. section 4.2]. Monitor renal
channel blockers (e.g., function, ECG for QT
nifedipine, nicardipine, prolongation, and other side
diltiazem, verapamil), effects closely.
amiodarone, danazol,
ethinylestradiol, lansoprazole,
omeprazole, the HCV
antivirals elbasvir/grazoprevir
and glecaprevir/pibrentasvir,
the CMV antiviral letermovir,
and the tyrosine kinase
inhibitors nilotinib, crizotinib
and imatinib and (Chinese)
herbal preparations containing
extracts of Schisandra
sphenanthera
In vitro the following May increase tacrolimus whole Monitor tacrolimus whole
substances have been shown blood trough concentrations and blood trough concentrations
to be potential inhibitors of increase the risk of serious adverse and reduce tacrolimus dose if
tacrolimus metabolism: reactions (e.g., neurotoxicity, QT needed [see section 4.2].
bromocriptine, cortisone, prolongation) [see section 4.4]. Monitor renal function, ECG
dapsone, ergotamine, for QT prolongation, and other
gestodene, lidocaine, side effects closely.
mephenytoin, midazolam,
nilvadipine, norethisterone,
quinidine, tamoxifen
Strong CYP3A4 inducers: May decrease tacrolimus whole It is recommended that
rifampicin, phenytoin, blood trough concentrations and concomitant use should be
carbamazepine, apalutamide, increase the risk of rejection [see avoided. If unavoidable,
enzalutamide, mitotane, or St. section 4.4]. patients may require an
John’s wort (Hypericum Maximal effect on tacrolimus blood increase in tacrolimus dose.
perforatum) concentrations may be achieved 1-2 Changes in tacrolimus dose
weeks after coadministration. The should be individualized and
effect may remain 1-2 weeks after adjusted as needed based on
completion of the treatment. tacrolimus trough
concentrations, which should
be assessed at initiation,
monitored frequently
throughout (starting within the
first few days) and re-
evaluated on and after
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lansoprazole (HOS-085166) letermovir (HOS-090621) diltiazem (HOS-086288) elbasvir (HOS-108814) isavuconazole (HOS-085186) nifedipine (HOS-086289) cortisone (HOS-114161) nicardipine (HOS-090619) pibrentasvir (HOS-086298) lidocaine (HOS-108866) carbamazepine (HOS-085618) crizotinib (HOS-116818) apalutamide (HOS-086212) tamoxifen (HOS-088380) quinidine (HOS-085593) glecaprevir (HOS-086297) azithromycin (HOS-088112) clotrimazole (HOS-090574) mephenytoin (HOS-109801) calcium (HOS-085615) imatinib (HOS-110212) grazoprevir (HOS-108815) danazol (HOS-085473) mitotane (HOS-112479) fluconazole (HOS-087945) bromocriptine (HOS-090620) nilvadipine (HOS-116826) gestodene (HOS-116824) ergotamine (HOS-086154) amiodarone (HOS-085596) tyrosine (HOS-108875) dapsone (HOS-088141) phenytoin (HOS-084531) enzalutamide (HOS-116829) nilotinib (HOS-086218) miconazole (HOS-115630) midazolam (HOS-086167) omeprazole (HOS-085912) verapamil (HOS-090602)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-02-28T09:35:00Z · SHA-256 17d795c1d27d8accdc66e175f0d8aaee387ebbb47a70a9d47988ed58a3ec39f7 · Passage c454d709eb3c54740f7cdf5a56983eb82d4ffba715e76287f20fe05820c48e36 · Zeichen 6843–11021 im Abschnitt
Gegenanzeigen · Evotaz
EVOTAZ 300 mg/150 mg film-coated tablets · Abschnitt 4.3 · PDF-Seite 3
HOS-221526 · Präparat HOS-216856
Co-administration with medicinal products that are strong inducers of the CYP3A4 isoform of
cytochrome P450 due to the potential for loss of therapeutic effect and development of possible
resistance (see section 4.5); co-administration is contraindicated with, but not limited to, the following
medicines:
carbamazepine, phenobarbital, phenytoin (antiepileptics)
St John's wort (Hypericum perforatum) (herbal product)
rifampicin (antimycobacterial)
apalutamide, encorafenib, ivosidenib (antineoplastics)
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): phenobarbital (HOS-085617) carbamazepine (HOS-085618) apalutamide (HOS-086212) encorafenib (HOS-086222) ivosidenib (HOS-112046) phenytoin (HOS-084531)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-07-10T17:52:00Z · SHA-256 40174e49ce0746a74379ea61b4f4b5adda6941da4dba06eb57dcc489e5e45bf8 · Passage 181f3e511c04cb7f28ff1ed8cf5c5d13d11cbc5429e31cc10e45611bec2fe31f · Zeichen 94–625 im Abschnitt
Wechselwirkungen · Evotaz
EVOTAZ 300 mg/150 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 8–9
HOS-221536 · Präparat HOS-216856
8
Concomitant use contraindicated
Co-administration of EVOTAZ with medicinal products that are strong inducers of CYP3A (such as
carbamazepine, phenobarbital, phenytoin, rifampicin, apalutamide, encorafenib, ivosidenib and
St. John’s wort [Hypericum perforatum]) may result in decreased plasma concentrations of atazanavir
and/or cobicistat, leading to loss of therapeutic effect and possible development of resistance to
atazanavir (see section 4.3 and Table 1).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): phenobarbital (HOS-085617) carbamazepine (HOS-085618) apalutamide (HOS-086212) encorafenib (HOS-086222) ivosidenib (HOS-112046) phenytoin (HOS-084531)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-07-10T17:52:00Z · SHA-256 40174e49ce0746a74379ea61b4f4b5adda6941da4dba06eb57dcc489e5e45bf8 · Passage 4e78db27f9595fcfb1306aca0e57bdc1e7ae67c0a1a6abf7303d1aa73744316b · Zeichen 1069–1533 im Abschnitt
Wechselwirkungen · Evotaz
EVOTAZ 300 mg/150 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 22–23
HOS-221601 · Präparat HOS-216856
22
Medicinal products by Interaction Recommendations concerning
therapeutic area co-administration
ANTIHISTAMINE AGENTS
astemizole EVOTAZ must not be used in Co-administration of EVOTAZ
terfenadine combination with medicinal with astemizole and terfenadine is
products that are substrates of contraindicated (see section 4.3).
CYP3A4 and have a narrow
therapeutic index.
ANTINEOPLASTICS AND IMMUNOSUPRESSANTS
Antineoplastics
irinotecan Atazanavir inhibits UGT and If EVOTAZ is co-administered
may interfere with the with irinotecan, patients should be
metabolism of irinotecan, closely monitored for adverse
resulting in increased irinotecan reactions related to irinotecan.
toxicities.
dasatinib Concentrations of these Concentrations of these medicinal
nilotinib medicinal products may be products may be increased when
vinblastine increased when co-administered co-administered with EVOTAZ
vincristine with EVOTAZ. resulting in the potential for
increased adverse events usually
The mechanism of interaction is associated with these anticancer
CYP3A4 inhibition by cobicistat. medicinal products.
apalutamide Potential substantial decrease in Co-administration of EVOTAZ
plasma concentrations of with apalutamide is
atazanavir and cobicistat, which contraindicated (see section 4.3).
may result in loss of virologic
response of EVOTAZ and
possible resistance to atazanavir
or to other protease inhibitors.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): dasatinib (HOS-086217) protease (HOS-085623) vinblastine (HOS-086220) apalutamide (HOS-086212) vincristine (HOS-086219) astemizole (HOS-085608) terfenadine (HOS-085607) irinotecan (HOS-112102) nilotinib (HOS-086218)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-07-10T17:52:00Z · SHA-256 40174e49ce0746a74379ea61b4f4b5adda6941da4dba06eb57dcc489e5e45bf8 · Passage 773e065afed4f3e08d21706bd91196f5a8376fcc7270850b72b849545980aa83 · Zeichen 47889–50155 im Abschnitt
Wechselwirkungen · Evotaz
EVOTAZ 300 mg/150 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 23
HOS-221602 · Präparat HOS-216856
The mechanism of interaction is
CYP3A4 induction by
apalutamide.
encorafenib Potential for loss of virologic Co-administration of EVOTAZ
ivosidenib response of EVOTAZ, with either encorafenib or
development of resistance, and ivosidenib is contraindicated (see
risk of serious adverse events section 4.3).
such as QT interval prolongation.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): apalutamide (HOS-086212) encorafenib (HOS-086222) ivosidenib (HOS-112046)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-07-10T17:52:00Z · SHA-256 40174e49ce0746a74379ea61b4f4b5adda6941da4dba06eb57dcc489e5e45bf8 · Passage db973240bcc17186478fea5e7221c7461031c286f889b199d87accdbd564abc2 · Zeichen 50187–50743 im Abschnitt
Wechselwirkungen · Lopinavir/Ritonavir Viatris (previously Ritonavir Mylan)
Lopinavir/Ritonavir Viatris 100 mg/25 mg film-coated tablets Lopinavir/Ritonavir Viatris 200 mg/50 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 12–13
HOS-222967 · Präparat HOS-217110
12
Co-administered drug by Effects on drug levels Clinical recommendation
therapeutic area Geometric Mean Change (%) in concerning co-administration with
AUC, Cmax , Cmin Lopinavir/Ritonavir Viatris
Mechanism of interaction
Clarithromycin Clarithromycin: For patients with renal impairment
Moderate increases in clarithromycin (CrCL < 30 ml/min) dose reduction of
AUC are expected due to CYP3A clarithromycin should be considered
inhibition by lopinavir/ritonavir. (see section 4.4). Caution should be
exercised in administering
clarithromycin with
Lopinavir/Ritonavir Viatris to patients
with impaired hepatic or renal
function.
Anticancer agents and kinase inhibitors
Abemaciclib Serum concentrations may be Co administration of abemaciclib and
increased due to CYP3A inhibition Lopinavir/Ritonavir Viatris should be
by ritonavir. avoided. If this co administration is
judged unavoidable, refer to the
abemaciclib SmPC for dosage
adjustment recommendations.
Monitor for ADRs related to
abemaciclib.
Apalutamide Apalutamide is a moderate to strong Decreased exposure of
CYP3A4 inducer and this may lead Lopinavir/Ritonavir Viatris may result
to a decreased exposure of in potential loss of virological
lopinavir/ritonavir. response.
In addition, co-administration of
Serum concentrations of apalutamide apalutamide and Lopinavir/Ritonavir
may be increased due to CYP3A Viatris may lead to serious adverse
inhibition by lopinavir/ritonavir. events including seizure due to higher
apalutamide levels. Concomitant use
of Lopinavir/Ritonavir Viatris with
apalutamide is not recommended.
Afatinib Afatinib: Caution should be exercised in
AUC: ↑ administering afatinib with
(Ritonavir 200 mg twice Cmax : ↑ Lopinavir/Ritonavir Viatris. Refer to
daily) the afatinib SmPC for dosage
The extent of increase depends on the adjustment recommendations.
timing of ritonavir administration. Monitor for ADRs related to afatinib
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): abemaciclib (HOS-086209) apalutamide (HOS-086212) lead (HOS-085592) afatinib (HOS-086207) clarithromycin (HOS-084517)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-01T11:16:00Z · SHA-256 0fed296c6994925fa007baa09781245b754a9daf71b55237d53885c6a4bb3537 · Passage d26e6496109db4fed9123d0c8b0cd8391350aa0295ae9bb545b7bf58c5812ecc · Zeichen 14507–18313 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.